Literature DB >> 30130749

The Clinical Significance of Body Weight Loss in Idiopathic Pulmonary Fibrosis Patients.

Yoshinari Nakatsuka1, Tomohiro Handa1, Maria Kokosi2, Kiminobu Tanizawa1, Silvia Puglisi2, Joseph Jacob3,4, Akihiko Sokai5, Kohei Ikezoe1, Kumiko T Kanatani6, Takeshi Kubo7, Hiromi Tomioka8, Yoshio Taguchi9, Sonoko Nagai10, Kazuo Chin11, Michiaki Mishima12, Athol U Wells2, Toyohiro Hirai1.   

Abstract

BACKGROUND: The significance of the nutritional status in idiopathic pulmonary fibrosis (IPF) is largely unknown. Temporal body weight (BW) change, a dynamic index of nutrition status, can detect the malnutrition more accurately than the conventional single-point body mass index evaluation.
OBJECTIVE: To investigate how the temporal BW change influences the clinical courses of IPF.
METHODS: This multicenter study enrolled IPF patients from four referral hospitals of interstitial lung diseases in Japan (the Japanese cohort, the derivation cohort) and the Royal Brompton Hospital (the UK cohort, the validation cohort). The annual rate of BW change from the initial presentation was evaluated. A > 5% decrease of BW was defined as a significant BW loss.
RESULTS: Twenty-seven out of 124 patients in the Japanese cohort and 13 out of 86 patients in the UK cohort showed significant BW loss. Patients with BW loss showed significantly worse survival in both cohorts. Multivariate analyses revealed that BW loss was an independent factor for decreased survival (Japanese cohort: p = 0.047, UK cohort: p = 0.013). A 6.1% loss of BW was chosen as the optimal cutoff value to predict the 2-year mortality from the initial presentation. The stratified analysis revealed that a 6.1% or greater BW loss could predict worse survival specifically in cases without a greater than 10% decline in forced vital capacity (FVC).
CONCLUSIONS: BW loss is independently associated with the survival of IPF patients, particularly when a decline in the FVC was not observed. Further studies are needed to understand the mechanisms underlying BW loss in IPF.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Idiopathic pulmonary fibrosis; Prognosis; Pulmonary function test; Weight loss

Mesh:

Year:  2018        PMID: 30130749     DOI: 10.1159/000490355

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  15 in total

1.  Choice of antifibrotic medication and disease severity predict weight loss in idiopathic pulmonary fibrosis.

Authors:  Apostolos Perelas; Jessica Glennie; Karen van Kerkhove; Manshi Li; Rachel G Scheraga; Mitchell A Olman; Daniel A Culver
Journal:  Pulm Pharmacol Ther       Date:  2019-09-10       Impact factor: 3.410

2.  Assessment of Alamandine in Pulmonary Fibrosis and Respiratory Mechanics in Rodents.

Authors:  Renata Streck Fernandes; Henrique Bregolin Dias; Wynnie Amaral de Souza Jaques; Tiago Becker; Katya Rigatto
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2021-05-18       Impact factor: 1.636

3.  Adiposity and Interstitial Lung Abnormalities in Community-Dwelling Adults: The MESA Cohort Study.

Authors:  Michaela R Anderson; John S Kim; Matthew Allison; Jon T Giles; Eric A Hoffman; Jingzhong Ding; R Graham Barr; Anna Podolanczuk
Journal:  Chest       Date:  2021-04-15       Impact factor: 10.262

Review 4.  Nutrition in Patients with Idiopathic Pulmonary Fibrosis: Critical Issues Analysis and Future Research Directions.

Authors:  Paola Faverio; Marialuisa Bocchino; Antonella Caminati; Alessia Fumagalli; Monica Gasbarra; Paola Iovino; Alessandra Petruzzi; Luca Scalfi; Alfredo Sebastiani; Anna Agnese Stanziola; Alessandro Sanduzzi
Journal:  Nutrients       Date:  2020-04-17       Impact factor: 5.717

5.  Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study [Letter].

Authors:  Leticia Orsatti; Josep Fortea; Manuel Quaresma
Journal:  Drug Des Devel Ther       Date:  2019-04-12       Impact factor: 4.162

6.  Nutritional assessment in idiopathic pulmonary fibrosis: a prospective multicentre study.

Authors:  Paola Faverio; Alessia Fumagalli; Sara Conti; Fabiana Madotto; Francesco Bini; Sergio Harari; Michele Mondoni; Tiberio Oggionni; Emanuela Barisione; Paolo Ceruti; Maria Chiara Papetti; Bruno Dino Bodini; Antonella Caminati; Angela Valentino; Stefano Centanni; Donatella Noè; Matteo Della Zoppa; Silvia Crotti; Marco Grosso; Samir Giuseppe Sukkar; Denise Modina; Marco Andreoli; Roberta Nicali; Giulia Suigo; Federica De Giacomi; Sara Busnelli; Elena Cattaneo; Lorenzo Giovanni Mantovani; Giancarlo Cesana; Alberto Pesci; Fabrizio Luppi
Journal:  ERJ Open Res       Date:  2022-03-07

7.  Comorbidities of Patients With Idiopathic Pulmonary Fibrosis in Four Latin American Countries. Are There Differences by Country and Altitude?

Authors:  Mauricio Gonzalez-Garcia; Emily Rincon-Alvarez; Maria Laura Alberti; Mauricio Duran; Fabian Caro; Maria Del Carmen Venero; Yuri Edison Liberato; Ivette Buendia-Roldan
Journal:  Front Med (Lausanne)       Date:  2021-06-17

8.  Body mass index and in-hospital mortality in patients with acute exacerbation of idiopathic pulmonary fibrosis.

Authors:  Nobuyasu Awano; Taisuke Jo; Hideo Yasunaga; Minoru Inomata; Naoyuki Kuse; Mari Tone; Kojiro Morita; Hiroki Matsui; Kiyohide Fushimi; Takahide Nagase; Takehiro Izumo
Journal:  ERJ Open Res       Date:  2021-06-28

9.  Eight months follow-up study on pulmonary function, lung radiographic, and related physiological characteristics in COVID-19 survivors.

Authors:  Shengding Zhang; Wenxue Bai; Junqing Yue; Lu Qin; Cong Zhang; Shuyun Xu; Xiansheng Liu; Wang Ni; Min Xie
Journal:  Sci Rep       Date:  2021-07-05       Impact factor: 4.379

10.  Decrements of body mass index are associated with poor outcomes of idiopathic pulmonary fibrosis patients.

Authors:  Tejaswini Kulkarni; Kaiyu Yuan; Thi K Tran-Nguyen; Young-Il Kim; Joao A de Andrade; Tracy Luckhardt; Vincent G Valentine; Daniel J Kass; Steven R Duncan
Journal:  PLoS One       Date:  2019-10-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.